文献速递慢阻肺肺栓塞与肺血管病

新西兰慢阻肺合并急性冠脉综合征患者β受体阻滞剂使用不足:全国随访研究

Underuse of beta-blockers by patients with COPD and co-morbid acute coronary syndrome: A nationwide follow-up study in New Zealand.
PubMed 文献 · Respirology · 2019-08-11

这项新西兰全国随访研究利用国家健康和药品发放数据,纳入83 435名≥45岁患者、共290 400人年随访,发现随访期间至少1次因ACS住院的2637名患者中,仅56.6%在首次住院后6个月内获得β受体阻滞剂,而阿司匹林和他汀分别为87.7%和81%。COPD严重程度较高者及既往无ACS和/或心衰史者接受β受体阻滞剂的可能性更低,提示对慢阻肺患者处方β受体阻滞剂存在特定顾虑。

要点

  • 慢阻肺合并ACS住院后6个月内仅56.6%使用β受体阻滞剂,远低于阿司匹林87.7%和他汀81%。
  • COPD严重程度越高,接受β受体阻滞剂的可能性越低。
  • 既往无ACS和/或心衰史者接受β受体阻滞剂的可能性也更低。

核心结论

  • 慢阻肺患者ACS住院后β受体阻滞剂使用率远低于新西兰ACS管理一般审计的预期。
  • 阿司匹林和他汀使用比例较高,且β受体阻滞剂发放率随COPD严重程度变化,提示对慢阻肺患者处方β受体阻滞剂存在特定顾虑。

研究设计与样本

  • 新西兰全国随访研究,利用国家健康和药品发放数据构建研究队列。
  • 队列纳入83 435名年龄≥45岁患者,共290 400人年随访。
  • 识别队列入组前和随访期间因ACS和/或心衰住院的患者,并确认药物使用情况。

主要发现

  • 随访期间至少1次ACS住院的2637名患者中,仅56.6%在首次住院后6个月内获得β受体阻滞剂。
  • 同一批ACS住院患者中,87.7%获得阿司匹林,81%获得他汀。
  • COPD严重程度较高的患者比严重程度较低者更不可能接受β受体阻滞剂。
  • 无既往ACS和/或心衰史的患者也更不可能接受β受体阻滞剂。

关键数值与推荐

  • 临床指南推荐ACS患者使用β受体阻滞剂和其他心血管预防药物。
  • 随访期间至少1次ACS住院的患者中,首次住院后6个月内β受体阻滞剂发放比例为56.6%。
  • 同一人群中阿司匹林发放比例为87.7%,他汀发放比例为81%。

临床怎么用

  • 对慢阻肺合并ACS患者应审视β受体阻滞剂处方不足问题,避免因COPD诊断而常规回避。
  • COPD严重程度较高及无既往ACS和/或心衰史的患者是β受体阻滞剂使用不足的高危人群,需重点关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Clinical guidelines recommend the use of beta-blockers and other cardiovascular prevention drugs in patients with acute coronary syndrome (ACS). Studies in several countries have found that beta-blockers are underused in patients with chronic obstructive pulmonary disease (COPD) and co-morbid heart disease, although most have only examined use in subgroups of patients. We undertook a nationwide follow-up study in New Zealand to describe the use of beta-blockers and other cardiovascular prevention drugs in patients with COPD and ACS. METHODS: National health and pharmaceutical dispensing data were used to derive the study cohort, identify patients who were admitted to hospital with ACS and/or heart failure before cohort entry and during follow-up, and ascertain drug use. RESULTS: The study cohort included 83 435 patients aged ≥45 years, with 290 400 person-years of follow-up. Among 2637 patients with ≥1 ACS admission during follow-up, only 56.6% received a beta-blocker in the 6 months following the first admission, while 87.7% and 81%, respectively, received aspirin and a statin. Patients with higher COPD severity were less likely to receive a beta-blocker than those with lower severity, as were those with no history of previous ACS and/or heart failure. CONCLUSION: Use of beta-blockers following an ACS admission was much lower than expected based on the findings of general audits of ACS management in New Zealand. Along with the higher proportions using aspirin and statins, and the differences in beta-blocker dispensing by COPD severity, this suggests a particular reluctance to prescribe beta-blockers to patients with COPD.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Parkin L, Quon J, Sharples K, et al. Underuse of beta-blockers by patients with COPD and co-morbid acute coronary syndrome: A nationwide follow-up study in New Zealand. Respirology. 2019. PMID: 31401813. doi:10.1111/resp.13662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。